For patients with rheumatic disease and hepatitis C infection: The end of interferon

RMD Open

Volumn 1, Issue 1, 2015, Pages

  Calabrese, Leonard H ^a   Cacoub, Patrice P ^b,c,d  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c Sorbonne Université   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018192760     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2014-000008     Document Type: Review

References (22)

1. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8.
2. Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 2013;369:1035-45.
3. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999;42:2204-12.
4. Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev 2012;8:348-57.
5. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014;61:373-95.
6. Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol 2007;19:61-6.
7. Jacobson IM, Cacoub P, Dal Maso L, et al. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 2010;8:1017-29.
8. Biggioggero M, Gabbriellini L, Meroni PL. Type I interferon therapy and its role in autoimmunity. Autoimmunity 2010;43:248-54.
9. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
10. Cacoub P, Terrier B, Saadoun D. Hepatitis C virus-induced vasculitis: therapeutic options. Ann Rheum Dis 2014;73:24-30.
11. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus peg-interferon-alpha/ribavirin compared with peg-interferon-alpha/ ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116:326-34; quiz 504-5.
12. Lidove O, Cacoub P, Hausfater P, et al. [Cryoglobulinemia and hepatitis c: worsening of peripheral neuropathy after interferon alpha treatment]. Gastroenterol Clin Biol 1999;23:403-6.
13. Cid MC, Hernandez-Rodriguez J, Robert J, et al. Interferon-alpha may exacerbate cryoblobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity. Arthritis Rheum 1999;42:1051-5.
14. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013;368:1907-17.
15. Saadoun D, Resche Rigon M, Thibault V, et al. Peg-IFNalpha/ ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2014;73:831-7.
16. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013;19:837-49.
17. Liang TJ, Ghany MG. Therapy of hepatitis C-back to the future. N Engl J Med 2014;370:2043-7.
18. Kohli A, Sims Z, Marti M, et al. Combination oral, hepatitis C antiviral therapy for 6 or 12 weeks: results of the SYNERGY trial. Conference on Retriviurses and Opprotunistic Infections. 2014.
19. Hoofnagle JH, Sherker AH. Therapy for hepatitis C-the costs of success. N Engl J Med 2014;370:1552-3.
20. Brunasso AM, Puntoni M, Gulia A, et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011;50:1700-11.
21. Afdhal NH, Zeuzem S, Schooley RT, et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat 2013;20:745-60.
22. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine 2000;79:47-56.